Teprotumumab confers long-term benefits in thyroid eye disease

Adults with active thyroid eye disease assigned the human monoclonal antibody teprotumumab experienced improvements in disease outcomes that persisted nearly 1 year after receiving the last trial dose, new study data show.
“These findings indicate that teprotumumab provided clinical benefits nearly 1 year after the last dose in people with thyroid eye disease participating in a placebo-controlled clinical trial,” Roger A. Dailey, MD, FACS, professor of ophthalmology at Oregon Health & Science University’s Casey Eye Institute, told Healio. “These data indicate that

Full Story →